All News

The FDA approved the supplemental biologics license for the expansion of IVIG (immune globulin, intravenous) use to children 2 years and older with primary humoral immunodeficiency, enabling earlier treatment and infection protection.

Data from a large New York State analysis found that sickle cell disease hospitalizations are becoming more severe over time, with significant regional disparities in outcomes, costs, and access to specialized care.

The temporary order will allow patients to continue receiving mifepristone via mail or at the pharmacies without an in-person visit to a doctor.

FDA approval of orforglipron may expand access to obesity treatment by offering a more convenient oral GLP-1 therapy option.

The interchangeable designation allows pharmacists to substitute Langlara for Lantus at the point of dispensing without prescriber intervention, a distinction that carries significant clinical and operational implications for pharmacy practice.

Ambulatory pharmacists can address mental health gaps, tackle stigma and SDOH, and power collaborative care, improving adherence and patient quality of life.

During Hepatitis Awareness Month, learn why hepatitis B vaccination and one-time screening help prevent silent infection and cut liver cancer risk.

Over a 10-year duration, these key elements have made a tremendous difference throughout a residency program.

Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.

Jordan Hill, PharmD, BCOP, talks about the impact of the updated NCCN guidelines for triple negative breast cancer.

New NCCN updates make sacituzumab govitecan a preferred first-line option in metastatic TNBC. Jordan Hill, PharmD, BCOP, explains the impact.

New trials show Pfizer’s Paxlovid (nirmatrelvir-ritonavir) speeds COVID-19 recovery in vaccinated patients, while hospitalization benefits fade.

Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.

Delaying hepatitis B vaccination beyond birth increases preventable infections, liver cancer deaths, and costs.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, from the University of Kansas Cancer Center talks about bispecifics and the value of building a network to communicate operationalizing these therapies across clinics.

CVS Specialty leaders detailed how clinical expertise, predictive analytics, and EHR connectivity are accelerating therapy starts and improving patient outcomes.

Andel's direct-to-employer model partners with Eli Lilly and other pharma companies to offer flexible, insurance-free GLP-1 access that benefits employers, patients, and manufacturers.

Renee’ Acosta, RPh, MS, discusses recent developments in the OTC market and key considerations pharmacy staff should prioritize when guiding patients in selecting appropriate over-the-counter therapies.

The agency's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List signals that large-scale compounding of these agents has no regulatory future, and carries immediate implications for pharmacy practice.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

The dextromethorphan-bupropion combination therapy targets NMDA and sigma-1 receptors, offering a first-in-class mechanism distinct from the only other approved agent for this indication.

Data from COA highlight operationalizing novel therapies in community cancer care.

Pharmacists help prevent communication breakdowns and improve coordination across oncology care teams.

Advanced therapy innovations are transforming cancer care but are outpacing delivery systems and community providers with specialty pharmacy support are the key to bridging the gap.

Coordinated pharmacist-led outreach, e-consults, and continuous glucose monitoring support improve diabetes outcomes, increase guideline-based therapy use, and impact total cost of care.